Contains Nonbinding Recommendations

Draft Guidance on Teriflunomide

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Teriflunomide
Dosage Form; Route: Tablet; oral
Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 14 mg
   Subjects: Healthy males, general population

   Additional comments: Applicants should exclude from the study male subjects wishing to father a child during the study. Since the half-life of teriflunomide is very long, the applicant may consider bioequivalence (BE) studies with parallel designs. For long half-life drug products, you may use an AUC truncated to 72 hours in place of AUC0-t or AUC0-∞.

2. Type of study: Fed
   Design: Single-dose, two-way crossover/parallel in vivo
   Strength: 14 mg
   Subjects: Healthy males, general population
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Teriflunomide in plasma
Bioequivalence based on (90% CI): Teriflunomide

Waiver request of in vivo testing: 7 mg based on (i) acceptable BE studies on the 14 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

Recommended Apr 2014; Revised Mar 2015